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Medicine  Volume 94, Number 23, June 2015met Coskun, MAbstract: Anemia is the most frequent complication of inflammatory
bowel disease (IBD), but anemia, mostly due to iron deficiency, has long
been neglected in these patients.
The aim was to briefly present the pathophysiology, followed by a
balanced overview of the different forms of iron replacement available,
and subsequently, to perform a systematic review of studies performed
in the last decade on the treatment of iron-deficiency anemia in IBD.
Given that intravenous therapies have been introduced in the last
decade, a systematic review performed in PubMed, EMBASE, the
Cochrane Library, and the websites of WHO, FDA, and EMA covered
prospective trials investigating the management of iron-deficiency
anemia in IBD published since 2004.
A total of 632 articles were reviewed, and 13 articles (2906 patients)
with unique content were included. In general, oral supplementation in
iron-deficiency anemia should be administered with a target to restore/
replenish the iron stores and the hemoglobin level in a suitable way.
However, in patients with IBD flares and inadequate responses to or side
effects with oral preparations, intravenous iron supplementation is the
therapy of choice. Neither oral nor intravenous therapy seems to
exacerbate the clinical course of IBD, and intravenous iron therapy
can be administered even in active disease stages and concomitantly
with biologics.
In conclusion, because many physicians are in doubt as to how to
manage anemia and iron deficiency in IBD, there is a clear need for theeiss, MD
unless such patients are intolerant or have an inadequate response,
whereas intravenous iron supplementation may be of advantage in
patients with aggravated anemia or flares of IBD because inflammation
hampers intestinal absorption of iron.
(Medicine 94(23):e963)
Abbreviations: ACD = Anemia of chronic disease, CD = Crohn’s
disease, CRP = Creactive protein, EMA = European Medical
Agency, FDA = US Food and Drug Administration, Hb =
Hemoglobin, IBD = Inflammatory bowel disease, IDA = Iron-
deficiency anemia, IL = Interleukin, kDa = Kilo Dalton, MCV =
Erythrocyte mean cell colume, MHC = Erythrocyte mean cell
hemoglobin concentration, MRI = Magnetic resonance imaging,
TFN = Tumor necrosis factor, TSAT = Transferrin saturation, UC =
ulcerative colitis.
INTRODUCTION
A nemia is the most common complication of inflammatorybowel disease (IBD)1,2 both at diagnosis and during flare-
ups,3,4 exceeding by far the frequency of extraintestinal mani-
festations (eg, rheumatic, dermatologic, and ophthalmo-
logic).5,6 Thus, in a systematic review from 2014 the
prevalence of anemia in patients treated in tertiary referral
centers with Crohn disease (CD) was 27% (95% confidence
interval 19–35), and 21% (95% confidence interval 15–27) for
ulcerative colitis (UC).1 This huge variation may be due to
differences in the study populations (eg, hospitalized patients
vs. outpatients) as well as in the definition of anemia. In recent
published studies of IBD patients, the calculated mean preva-
lence was 20% among outpatients7 and 68% among hospital-
ized patients.8 Furthermore, anemia is more common in CD
than in UC, and women with CD are at a higher risk for anemia.9
Anemia in IBD is mostly multifactorial, resulting, on the
one hand, from chronic intestinal blood loss from inflamed
intestinal mucosa combined with impaired iron absorption
mainly as a consequence of inflammation but also in association
with intake of proton pump inhibitors, persisting H. pylori
infection or reduced food and thus impaired dietary iron uptake.
Moreover, cytokines and acute phase proteins being induced
upon inflammation impair iron availability for erythropoiesis;
cause, a blunted biological activity of erythropoietin, and an
inflammation driven impairment of erythroid progenitor cell
proliferation.10,11 In general, anemia is found in various chronic
inflammatory diseases, including cancer, infection, and auto-
immune diseases, and this so-called anemia of chronic diseaseation is more prevalent in patients with
those responding poorly to therapy.11
in IBD patients occasionally may be
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FIGURE 1. Regulation of systemic iron homeostasis by hepcidin.
Enterocytes and monocytes release Fe2þ via the iron exporter
ferroportin, which is then oxidized to Fe3þ and transported via the
bloodstream. Liver-derived hepcidin inhibits iron efflux from these
cells by binding to ferroportin, which promotes ferroportin intern-
alization and degradation. The synthesis of hepcidin in the liver is
Medicine  Volume 94, Number 23, June 2015induced or aggravated by drugs used for IBD treatment or by
vitamin deficiencies, as well as rarely for various other reasons
(eg, renal insufficiency, hemolysis, and innate hemoglobino-
pathies),12 and a recent population based study revealed that
patients with IBD have an insufficient intake of iron in their
diet.13
Treatment of iron-deficiency anemia is very likely to have
a beneficial impact on the affected patients because various
organs may be disturbed as a result of the anemia [eg, central
nervous system (impaired cognitive function, fatigue, ‘‘restless
syndrome,’’ and depression), immune system (impaired reac-
tive oxygen species production and alterations in cell func-
tions), cardiorespiratory system (exertional dyspnea,
tachycardia, palpitations, cardiac hypertrophy, systolic ejection
murmur, and risk of cardiac failure), vascular system (hypother-
mia and pallor of skin), genital tract (loss of libido and men-
strual problems), and gastrointestinal tract (anorexia, nausea,
and motility disorders)].14,15
The aims of this paper are to clarify the pathophysiology
of anemia of IBD, to provide a balanced overview of the
various forms of treatment, focusing on the approaches to iron
replacement that are available for management, and to perform
a systematic review to summarize the latest evidence (ie,
within the last decade, during which intravenous regimens
have been added to the therapeutic armamentarium) with
respect to the diagnosis and treatment of choice for anemia
in IBD. Finally, based on our systematic review, we aimed to
provide an updated decision algorithm for the management of
anemia in IBD.
PATHOPHYSIOLOGY OF ANEMIA IN
INFLAMMATORY BOWEL DISEASE
Iron deficiency in IBD is caused by numerous factors,
including increased iron loss from bleeding due to gastrointes-
tinal inflammation and decreased iron absorption as a con-
sequence of short bowel syndrome, loss of appetite during IBD
flares, and inflammation-driven blockage of intestinal iron
acquisition and macrophage iron reutilization.16 The average
adult harbors at least 3–4 g of stored iron that is balanced
between physiologic iron loss and dietary intake. Most iron is
incorporated into hemoglobin (Hb), whereas the remainder is
stored as ferritin, myoglobin, or within iron-containing
enzymes. About 20–25mg of iron is needed daily for heme
synthesis. Approximately 1–2mg of this requirement comes
from dietary intake, and the remainder is acquired by recycling
iron from senescent erythrocytes.17,18 Total iron loss averages
about 1–2mg/day, mostly via the feces and cellular desquama-
tion from the skin and intestine, as well as additional losses
through menstruation.19,20
Body iron homeostasis is regulated systemically by
multiple mechanisms, among which the interaction of the
liver-derived peptide hepcidin with the major cellular iron
exporter ferroportin is of pivotal importance (Figure 1). The
formation and release of hepcidin are induced by iron loading
and inflammatory stimuli such as interleukin 1 (IL-1) or IL-6,
whereas its synthesis is blocked by iron deficiency, hypoxia,
and anemia.21–23 Hepcidin targets ferroportin on the cell sur-
face, resulting in ferroportin internalization and degradation and
blockage of cellular iron egress.22 Whereas low circulating
hepcidin levels enable an efficient transfer of iron from enter-
Nielsen et alocytes and macrophages to the circulation in order to overcome
iron deficiency, iron is retained in these cells when hepcidin
levels are high and serum iron levels drop23,24 (Figure 1).
2 | www.md-journal.comFurthermore, inflammatory cytokines can directly inhibit iron
absorption and stimulate the uptake and retention of iron in
macrophages via hepcidin-independent pathways.21 Of interest,
circulating hepcidin levels have an impact on the efficacy of
oral iron therapy and can predict nonresponsiveness,25 which is
in line with experimental data demonstrating reduced intestinal
ferroportin expression and iron absorption in individuals with
increased hepcidin levels primarily as a consequence of inflam-
mation.24 As a result, anemia develops and is characterized by
low circulating iron levels and an iron-restricted erythropoiesis
in the presence of high iron stores in the reticuloendothelial
system, reflected by normal or high levels of ferritin. Cytokine-
driven induction of hepcidin expression and the direct effects of
cytokines on iron trafficking in macrophages play a decisive
role in the development of this type of anemia (ie, anemia of
chronic disease or the anemia of inflammation), by retaining
iron in the reticuloendothelial system and blocking iron absorp-
tion, which results in an iron-limited erythropoiesis.11,26 The
latter is reflected clinically by a reduced transferrin saturation
that according to national guidelines is below 16% or 20%.27 In
addition, cytokines and chemokines further contribute to ane-
mia by negatively affecting the activity of erythropoietin, by
inhibiting the proliferation and differentiation of erythroid
progenitor cells, and by reducing the circulatory half-life of
erythrocytes.11
Importantly, patients with active IBD suffer from chronic
blood loss due to mucosal bleeding, which often causes true iron
deficiency, as reflected by low ferritin levels.28,29 Moreover,
true iron deficiency and anemia reduce hepcidin expression.
These effects are transmitted by iron-deficiency-mediated inhi-
induced by iron and inflammatory signals and suppressed by iron
deficiency, anemia, or hypoxia.bition of SMAD signaling in hepatocytes, anemia-induced and
erythropoiesis-driven formation of hepcidin inhibitors such as
erythroferron and growth differentiation factor 15 (GDF-15),
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
and hypoxia-driven blockade of hepcidin formation via platelet-
derived growth factor BB (PDGF-BB) or hypoxia-inducible
factors (HIFs).30–34 Thus, in the presence of both inflammation
and true iron deficiency due to bleeding in IBD, circulating
hepcidin levels decrease because anemia and iron-deficiency
regulatory signals dominate inflammation-driven hepcidin
induction.34,35 Therefore, truly iron-deficient patients, even
in the presence of systemic inflammation, are able to absorb
considerable amounts of iron from the intestine.22,24
Furthermore, vitamin deficiencies (eg, vitamin B12, folic
acid, and vitamin D) due to either intestinal inflammation or
extensive bowel resection contribute to the development of
anemia.29,36 Drugs used for the treatment of patients with IBD,
such as proton pump inhibitors, sulfasalazine, methotrexate, and
thiopurines, as well as functional impairment of the intestine
due to inflammation or previous surgery, may aggravate anemia
by negatively affecting iron absorption or erythropoiesis.37
TREATMENT OF ANEMIA
The primary treatment of anemia of chronic disease is the
cure of the underlying disease which in most cases leads to
resolution or at least improvement of anemia unless other patho-
physiological factors or deficiencies are involved.4,9,11,12,15 In
cases of severe anemia (ie, Hb < 7–8 g/dL),38,39 specifically
when it develops rapidly on the basis of acute gastrointestinal
bleeding, or if the patient suffers from comorbidities resulting in
Medicine  Volume 94, Number 23, June 2015aggravation of anemia-related symptoms such as coronary heart
disease or chronic pulmonary disease, application of blood
transfusionsmight be treatment of choice because this can rapidly
FIGURE 2. Iron absorption from oral or intravenous iron supplementat
result in a daily absorption of 10–20mg elemental iron (predom
supplementation mainly consists of the Fe2þ (ferrous) form that can
Fe3þ (ferric) form, contains 10–30% of heme-bound iron, whereas the
formulations are taken up by enterocytes via different pathways with
ferroportin. Here, Fe2þ becomes oxidized to Fe3þ and specifically recog
target cells in the liver, bone marrow, and other tissues and organ
administered as high doses of iron directly in the bloodstream in its
(leading to an increase in their iron content), which redeliver Fe3þ to
transported to target cells.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.correct anemia and increase Hb levels.11,12,15,40 However, the
indication for transfusions must be considered carefully as nega-
tive effects have been documented.40,41 These include an
increased mortality in patients with liberal use of blood transfu-
sions for the treatment of upper gastrointestinal bleeding,42 an
increased nosocomial infection rate and mortality among inten-
sive care patients,43 higher frequency of surgical site infections,44
the occurrence of transfusion-related anaphylactic reactions
along with a small but residual risk for transmitting infec-
tions.45–47 Of note, if other easy-to-treat reasons contributing
to anemia have been identified, such as vitamin deficiency, these
should be corrected accordingly.
VARIOUS FORMS OF IRON REPLACEMENT
As imbalances of iron homeostasis are the major reason for
anemia in IBD, this treatment strategy is in the focus of this
review. Before going to the systematic analysis of clinical trials
using oral and intravenous regimens, the currently available
iron supplementation options are highlighted.
Oral Regimen
Oral iron supplementation is frequently used to treat iron-
deficiency anemia partly because of an established safety profile,
ease of administration, and a general low cost, although in a
pharmacoeconomical setting the cost-effectiveness is more
Treatment of Iron-Deficiency Anemia in IBDimportant.16 Oral iron supplements are available as either diva-
lent Fe2þ (ferrous) salts or a trivalent Fe3þ (ferric) form coupled
with sugar complexes.48 The most widely used preparations are
ion. Oral preparations of iron supplements are given as tablets and
inantly in the duodenum and upper jejunum). The oral iron
be absorbed directly by enterocytes. Dietary iron, mostly in the
majority consists of nonheme iron (Fe3þ form). These 2 dietary iron
subsequent yield of Fe2þ which is exported to the circulation by
nized and bound by transferrin and transported via bloodstream to
s for use or storage. Intravenous iron supplementation can be
trivalent Fe3þ form, which is taken up by circulating monocytes
the blood circulation, where it is bound by plasma transferrin and
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ferrous sulfate, ferrous gluconate, and ferrous fumarate contain-
ing the ferrous form of iron because of the poor solubility of
ferric-containing formulations. For absorption by enterocytes,
Fe3þ needs to be reduced toFe2þ (Figure 2),which is catalyzedby
a membrane-bound ferric reductase and augmented by ascorbic
acid.49 Indeed, ascorbic acid (or vitamin C) facilitates increased
absorption of oral iron.50 However, a recent phase III study has
reported that oral ferric maltol [a new compound under review by
the European Medicines Agency (EMA)] is an efficient alterna-
tive treatment option for iron-deficiency anemia in IBD patients
who are unresponsive to or intolerant of oral ferrous products.51
Although the optimal dose in IBD has not been established,
the commonly recommended dose of oral iron for the treatment
of iron deficiency is 50–200mg/day of elemental iron once
daily,52 but only a maximum of 10–20mg/day of iron is
absorbed in iron-deficient patients.49,53 Given that a high
proportion of nonabsorbed ingested iron remains in the gut,
oral iron supplementation is associated with gastrointestinal
side effects such as nausea, vomiting, diarrhea, abdominal pain,
and constipation in up to 20% of patients.3,16 Nausea and
abdominal discomfort generally occur 1–2 hours after intake
and tend to be dose related, although other gastrointestinal side
effects such as constipation and diarrhea are idiosyncratic.52,53
Nonetheless, delayed-release enteric-coated iron tablets may be
used in patients reporting such intolerances. However, these
tablets may not be absorbed as effectively as standard prep-
arations because they dissolve slowly in the duodenum, where
most iron is absorbed (Figure 2).
Most of the anxiety regarding the use of oral iron therapy
comes from studies in animal models of IBD that have provided
contradictory evidence regarding exacerbation and/or improve-
ment of inflammation.54,55 However, in humans, the evidence
has been more controversial, and even though there is no
convincing evidence that oral iron given in therapeutic dosages
is effective in humans with activate IBD,56,57 it is established
that iron availability in the gut has a significant impact on the
composition of the microbiome,58 which has a central role in the
pathogenesis of IBD.59 The clinical significance of such
Nielsen et alchanges remains speculative, but the evidence suggests that
nutritional interventions may influence disease activity in
patients with IBD.60
TABLE 1. Characteristics of Different Intravenous Iron Preparatio
Iron Preparation Molecular
Weight (kDa)
Carbohydrate Shell
Iron dextran, low
molecular weight
73 Dextran (branched
polysaccharide)
Iron sucrose 43 Sucrose (disaccharide)
Iron gluconate 37 Gluconate (monosacchari
Ferric carboxymaltose 150 Carboxymaltose
(branched polysacchari
Iron isomaltoside 1000 150 Isomaltoside
(linear oligosaccharide
Ferumoxytol

721 Polyglucose sorbitol
carboxymethylether

Not yet approved for IBD in Europe. The information given is from ir
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Parenteral iron administration traditionally has been
reserved for patients with intolerance or inadequate response
to oral iron and for patients in whom a rapid increase in iron
stores (replenishment) is desired (eg, patients scheduled for
surgery in the short term).3,4,12 This approach is reflected in the
indications approved by the US Food and Drug Administration
(FDA) for a number of intravenous iron preparations,61 as well
as the EMA.62 Although severe or life-threatening anaphylactic
reactions upon intravenous iron administration occur very
infrequently and have been mainly observed with high mole-
cular weight dextrans in the past, the risk for such severe
adverse reactions is much lower with currently used prep-
arations, including high molecular weight iron components.63
Compared with oral iron, intravenous iron seems to increase Hb
and iron storage and improves quality of life more rapidly but not
always more effectively.58,64 In addition, disadvantages
include—apart from a generally higher cost—a risk of infu-
sion-related adverse reactions, including anaphylaxis, which
means that staff should be alerted to manage such potentially
life-threatening situations.63 Today, 6 intravenous iron prep-
arations are available, including iron dextran, iron sucrose, and
iron gluconate and, the more recently licensed compounds, ferric
carboxymaltose, iron isomaltoside 1000, and ferumoxytol16,65,66
(Table 1). The structures of these new preparations are more
stable and allow only a low level of labile iron to be released into
the circulation, resulting in improved safety profiles.
Iron dextran exists in 2 stable forms: a low- (73 kDa) and a
high-molecular-weight (165 kDa) complex, although the latter
has been associated with an increased risk of anaphylaxis and
anaphylactoid reactions.67–70 Thus, only low-molecular-weight
iron dextran is currently available in Europe71 and can be given
at a maximum single dose of 200mg over a minimum of 30min.
Given the risk of anaphylactoid reactions, it was previously
recommended to administer a test dose of iron dextran (ie,
0.5mL at a gradual rate over 2–5min) before giving a full dose,
but the EMA no longer recommends this precaution.62
Iron sucrose (43kDa) and iron gluconate (37kDa) are less
stable and therefore canbe administrated in amaximal single dose of
Medicine  Volume 94, Number 23, June 2015only 200mg (300mg in some countries) over a (minimum) infusion
time of 30minutes72 or 62.5mg (in some countries 125mg) over an
infusion time of 5–10min,73 respectively, without a test dose.
ns
Complex
Stability
Maximum Approved
Single Dose
Maximum
total Dose
High 200mg (<30 min) 20mg/kg
Moderate 200mg (30 min) 7mg/kg (300mg in
some countries)
de) Low 62.5mg (5–10 min) 62.5mg (125mg in
some countries)
de)
High 1000mg (15 min) 20mg/kg
)
High 1000mg (15 min) 20mg/kg
High 510mg (1 min) 510mg
on deficiency anemia in patients with chronic kidney disease.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
However, higher dosages74 or accelerated infusion rates75 are
associated with increased adverse events such as transient hypoten-
sion due to the release of labile iron. Thus, iron dextran, iron sucrose,
and iron gluconate preparations typically require multiple adminis-
trations of lower doses to replenish iron stores.
The introduction of more advanced iron formulations,
however, has permitted high-dose infusions (without test dos-
ing) with minimal side effects because of the low levels of labile
iron released during administration. Ferric carboxymaltose76–80
and iron isomaltoside 100081,82 are highly stable 150-kDa
complexes that are approved for clinical use. Their robust
structures allow controlled and safe delivery of high-dose iron
to the cells. Ferric carboxymaltose can be administered effec-
tively and efficiently with a maximum single dose of 1000mg
over at least 15minutes at a minimal interval of once per
week.81 The structure of iron isomaltoside 1000 allows for
administration of high single doses of up to 20mg/kg of body
weight within 15minutes.81 Currently, there are limited data on
iron isomaltoside 1000 in the treatment of iron-deficiency
anemia in patients with IBD,82 although clinical trials are
currently ongoing. Ferumoxytol is a much larger complex with
a molecule weight of 721 kDa, which allows the drug to be
given rapidly in relatively large doses. Although ferumoxytol is
not yet approved for IBD in Europe, the current recommended
intravenous dosing of this drug for patients with iron deficiency
anemia due to chronic kidney disease is up to 510mg in less
than 1min, with a second dose of 510mg administered 3–8 days
later.83 Although limited data are available on ferumoxytol in
the treatment of anemia in patients with various gastrointestinal
diseases,84 there are indications that the paramagnetic nature of
ferumoxytol can interfere with MRI examinations.85 Because
MRI is an important diagnostic tool in the management of
patients with IBD, this drawback may seriously hamper its use
in this patient population. Further, in a recent analysis of
different intravenous iron products in the United States, fer-
umoxytol had the highest rate for adverse events per million
units sold of all products,86 impeding its benefit–risk ratio, and
since March 2015 it carries a boxed warning by FDA regarding
potentially life-threatening allergic reactions.
Although different iron preparations have different side-
effect profiles,68 the most frequently reported complaints after
infusion of large-molecule iron complexes are itching, dyspnea,
wheezing, and myalgias. In this context, it should be noted that
acute myalgia at the first administration of intravenous iron
(without any other symptoms) that ablates spontaneously within
minutes (ie, the so-called Fishbane reaction) does not recur at
rechallenge.87 Other, more certain side effects include hypoten-
sion, tachycardia, stridor, nausea, dyspepsia, diarrhea, and skin
flushing, including periorbital edema. Serious side effects are
rare88 and include cardiac arrest,89 but such problems are more
common with older, mostly dextran-containing preparations.90
Therefore, close monitoring for signs of hypersensitivity during
and for at least 30min after each administration of an intrave-
nous iron formulation and reduction of the infusion speed on
occurrence of discomfort are recommended.62
SYSTEMATIC REVIEW OF CLINICAL TRIALS SINCE
2004 METHODS
Search Strategy
Medicine  Volume 94, Number 23, June 2015A systematic review was performed adhering to the guide-
lines established by the PRISMA Statement.91 A bibliographic
search was performed in the PubMed and EMBASE databases
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.from January 2004 (ie, before the era of intravenous iron
supplementation) to March 2015 using combinations of the
following medical subject heading search terms: ‘‘inflamma-
tory bowel disease’’ or ‘‘Crohn’s disease’’ or ‘‘ulcerative
colitis’’ and ‘‘iron deficiency’’ or ‘‘anemia.’’ No prepublished
protocol is accessible. Other sources of information were the
Cochrane Library and the websites of WHO, FDA, and EMA.
Figure 3 is a flowchart summarizing study identification
and selection.
Selection Criteria
For the quality assessment, only original prospective studies
evaluating the treatment of iron-deficiency anemia (ie, normal-
ization of Hb concentration) in IBD patients with a minimum
observation time of 4 weeks were included. Outcome assessment
included correction of iron deficits causing anemia in IBDpatients.
Only English-language articles, excluding reviews and nonhuman
investigations, were evaluated. Subsequently, articles were
selected based on clinical relevance, and reference lists of relevant
articles were hand searched to identify any additional studies.
Data Abstraction
Two authors (O.H.N. and M.C.) independently identified
candidate articles from the results of the initial search on the
basis of title and abstract. Subsequently, these 2 authors inde-
pendently reviewed the full texts of candidate articles to identify
interventions and assess study quality. Any discrepancies
between the independent searchers were resolved in consensus
with the 2 other authors (M.A. and G.W.).
Data Synthesis and Analysis
The literature search identified 13 randomized, controlled
studies and prospective studies with and without control
groups.51,54,64,69,72,77–80,84,92–94 Because of the considerable
diversity in study designs (eg, oral and low- or high-dose
intravenous drugs with different compositions), however, the
authors were unable to conduct a meta-analysis.
The study was exempt from approval by the Scientific
Ethics Committee of the Copenhagen Capital Region because
the analysis involved only deidentified data, and all 13 studies
included were granted individual ethics approval.
Funding Source
The National Danish and Austrian Research Funds funded
the research but had no role in the design, conduct of the study,
or preparation of the manuscript.
RESULTS
The systematic search yielded a total of 632 studies, of
which 13 prospective trials met the above-mentioned inclusion
criteria (Figure 3) and included 2906 patients. Only data
acquired from the systematic search are included in this section,
and key data from each study are presented in Table 2 with
results based on the conclusion of each individual study.
From the systematic review, it was revealed that apart from
the WHO definitions of anemia38 (ie, Hb level of <13 g/dL for
men and <12 g/dL for women), transferrin saturation [TSAT;
ie, the quotient of iron concentration (mmol/L) divided by
transferrin concentration (mg/dL) in fasting blood samples
Treatment of Iron-Deficiency Anemia in IBDmultiplied with 70.9 stated as a percentage] of <20%,
and serum ferritin concentration of <30mg/L with a serum
C-reactive protein (CRP) level within the normal range or a
www.md-journal.com | 5
Nielsen et al Medicine  Volume 94, Number 23, June 2015ferritin concentration of <100mg/L with an elevated serum
CRP level comprised the laboratory tests used in the 13 studies
for the diagnosis and assessment of iron-deficiency anemia
in IBD.
Only 9 trials including oral iron supplementation in IBD
patients have been published since 2004,51,54,64,69,72,79,80,92,94
but oral supplementation is from the published data well
tolerated and has a positive effect on both Hb levels and body
iron parameters (Table 2). From the studies included it seems
that milder side effects (ie, abdominal discomfort, diarrhea,
nausea, and vomiting) occurred less often after intravenous
therapy as compared with oral therapy69,72,79,92,94 although 1
study did not report such differences.64 From the studies
included no comparison between side effects to various forms
of oral supplementations was, however, performed. From an
examination of the available data, it was apparent that there are
no data indicating that oral iron supplementation exacerbates
symptoms of the underlying IBD. Only 1 study in this systema-
tic review reported worsening of disease activity in 2 of 33
patients with UC (but not in patients with CD).54 However, in
this study, the IBD quality-of-life scores improved significantly
(P¼ 0.016) at the same time,54 and when the 8 studies using oral
iron supplementation were evaluated, it was apparent that an
adequate level of evidence is provided to address the safety of
oral iron supplementation in IBD. Of note, a very recent study
with oral ferric maltol suggests that this drug may be an
alternative for patients who are unresponsive to or intolerant
of formulations containing ferrous salts,51 which needs to be
FIGURE 3. Flowchart of study screening process.confirmed in future studies
In the trials included in the systematic review, it was
observed that administration of intravenous iron in IBD patients
6 | www.md-journal.comfrequently resulted in higher ferritin levels but not higher
hemoglobin concentrations compared with oral iron supple-
mentation in mild anemia (Hb  10 g/dL) and short-term
follow-up,64,79,80,94 whereas in more aggravated iron deficiency
anemia intravenous iron supplementation was superior to oral
treatment regarding increase of Hb.69,80,92,94 Nevertheless, in all
studies included in the systematic review, oral supplementation
was administered for a minimum of 4 weeks with the target of
normalizing Hb values.
In patientswith IBD flares who have an inadequate response
to experienced side effects with oral preparations, intravenous
iron supplementation is the therapy of choice because it does not
seem to exacerbate the clinical course of IBD and, in patients
undergoing biological therapy with tumor necrosis factor (TNF)
inhibitors, concomitant iron supplementation may be prescribed
without affecting the disease course/activity.93
Finally, it was established that the correction of anemia
with iron supplementation is associated with a relevant
improvement in the patient’s quality of life.92
DISCUSSION
For a long time, it was thought that the clinical symptoms
of anemia occurred only when the Hb level dropped abruptly95
and, conversely, that patients would adapt to lowHb levels if the
anemia developed slowly. This led to the concept of asympto-
matic anemia. In truth, the term asymptomatic seems to reflect
the fact that impairments in physical condition, quality of life,
cardiovascular performance, and cognitive function may be
unrecognized by both patients and their physicians. Therefore,
the process of adaptation in chronic anemia would seem to be
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Controlled Trials of Iron Deficiency Anemia Since 2004 Included in the Systematic Review
Authors
Route of
Administration
Number of Patients,
Disease Activity, and
Follow-Up Time (wk)
Design, Inclusion Criteria,
and End Point/Target Findings
de Silva54 Oral ferrous sulfate
(600mg/day)
57 patients with IDA
(22 with CD, 18 with
UC (both groups
quiescent to moderate
disease activity), and
17 non-IBD)
4 weeks
Comparative study Hb
< 13 g/dL, s-ferritin
< 12mg/L, hypochromic
erythrocyte count >4%
Target: normalization
of Hb
Oral iron supplementation
was rarely (6%)
associated with increased
disease activity of IBD.
Four weeks of
supplementation caused
significant rises in Hb
and iron stores
(i.e., s-ferritin levels).
Schroder72 Oral (iron sulfate
100–200mg/day for
6 weeks; n¼ 24) and
low-dose intravenous
sucrose (200mg 1 to
2 times per week for
5 weeks; n¼ 22)
46 (29 CD, 17 UC) with
quiescent and active
disease (not specified)
>5 weeks
Randomized either oral
or intravenous
Hb < 11.0 g/dL < or
10.5 g/dL ,, TSAT
 20% or s-ferritin
 20mg/L
Target: change in Hb
Equal short-term efficacy
and safety of intravenous
sucrose and oral iron
supplementation for
treatment of iron
deficiency anemia in
IBD (Hb, s-ferritin conc.
and TSAT). Iron
supplementation did
not affect disease activity.
Katsanos93 Intravenous iron sucrose
(dose 200–400 mg/
infusion)
61 patients with ‘‘difficult to
treat’’ IBD (eg, refractory
disease in need of
infliximab) with
quiescent to severe
disease activity
12 weeks (iron sucrose
was interrupted at a
transferrin saturation
of >50%)
Open intravenous iron
administered less than
12 weeks from last
infliximab dose
Hb < 12 g/dL, TSAT
< 20%
Target: Hb 12 g/dL
Infliximab and iron sucrose
can be administered in
combination with good
tolerance, efficacy
(Hb and TSAT),
and overall safety. Iron
supplementation did not
affect disease activity.
Kulnigg79 Intravenous ferric
carboxymaltose
(1000mg; n¼ 136) or
oral ferrous sulfate
(100mg b.i.d.; n¼ 60)
196 patients (56 CD,
140 UC) with quiescent
to severe disease activity
12 weeks
Randomized, open-label,
comparative; endpoint
was change in Hb
from baseline to
week 12
Hb  10 g/dL, TSAT
< 20% or s-ferritin
< 100 mg/L
Target: change of Hb
Ferric carboxymaltose is not
inferior to ferrous sulfate
in terms of Hb, serum
ferritin, and TSAT
change over 12 weeks.
Iron supplementation did
not affect disease activity.
Gisbert92 Oral (525mg ferrous
sulfate; n¼ 78) and
low-dose intravenous
sucrose (200mg twice
a week; n¼ 22) based
on Ganzoni’s formula
100 patients (59 CD, 41 UC)
with quiescent and active
disease (not specified)
>12 weeks
Oral treatment at baseline
for 3 months; insufficient
response (ie, 1 g/dL)
continued for extra
3 months; no response
(ie, <1 g/dL): sucrose
Hb < 13 g/dL < or
<12 g/dL
, plus at least 1 of the
following: s-iron
< 59mg/dL, s-ferritin
< 30mg/L, TSAT
< 12%, or s-transferrin
> 400mg/dL
Target: normalization
of Hb
Normalization of Hb
concentration was found
in the majority of IBD
patients on oral treatment,
whereas low-dose (sucrose)
was an effective alternative
in more severe anemia or
intolerant patients.
Iron supplementation did
not affect disease activity.
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Authors
Route of
Administration
Number of Patients,
Disease Activity, and
Follow-Up Time (wk)
Design, Inclusion Criteria,
and End Point/Target Findings
Lindgren94 Oral (iron sulfate
800 mg/day, n¼ 46) and
low-dose intravenous
iron sucrose 200mg
every week or every
second week; n¼ 45)
91 patients (44 CD,
47 UC) all in
quiescent stage
20 weeks
Randomized, controlled,
open-label study
Hb  11.5 g/dL, TSAT
< 20% or s-ferritin
< 30mg/L
Target: increase of Hb
Intravenous iron sucrose
treatment is superior to
oral iron in correcting Hb,
serum ferritin conc.,
and TSAT.
Iron supplementation did
not affect disease activity.
Evstatiev77 Intravenous high-dose
ferric carboxymaltose
(500–1000 mg/infusion,
n¼ 244) versus low-dose
iron sucrose
(200 mg/infusion,
n¼ 239)
475 patients with IDA
(160 CD, 315 UC) in
remission to moderate
disease activity
12 weeks
Randomized, controlled,
open-label study
Hb < 13 g/dL <
or <12 g/dL
,, TSAT < 20%,
s-ferritin < 100mg/L
Target: Hb increase
 2 g/dL
A simplified fixed-dose
ferric carboxymaltose
regimen based on weight
and baseline Hb is well
tolerated and superior to
the Ganzoni-calculated
iron sucrose dosing
regarding efficacy,
compliance, and safety.
Iron supplementation did
not affect disease activity.
Khalil69 Oral (elemental iron)
primarily ferrous sulfate
(but also ferrous
fumarate,
polysaccharide–iron
complex, sodium
feredetate, and ferrous
gluconate, mean dose
103 mg/day) versus
low-dose iron–dextrane
(mean dose of 949 mg)
66 IBD patients who earlier
had received iron
supplementation (44 CD,
22 UC in remission or
active disease not
specified) received either
oral or intravenous
treatment (1:1)
8 weeks
Case-matched study in
clinical practice
Hb < 13 g/dL <
or <12 g/dL
,, TSAT < 16%,
s-ferritin < 30mg/L with
CRP in normal range
and < 100mg/L with
elevated CRP
Target: increase of Hb
Oral iron should be used
as first-line treatment,
particular in mild anemia
(10 g/dL) whereas
intravenous iron
treatment is suitable
for those intolerant of
or responding poorly to
oral iron as evaluated
from rise in Hb.
Iron supplementation did
not affect disease activity.
Evstatiev78 Intravenous high-dose ferric
carboxymaltose
(500mg/infusion)
versus placebo
245 nonanemic IBD
patients who had
previously completed the
Evstatiev (2011) study
(77) (76 CD, 169 UC
in remission to moderate
disease activity)
8 months [from
completing
Evstatiev (2011)
study (77)
Randomized, single-blind
study to determine if
administration of intra-
venous ferric carboxy-
maltose prevents
recurrence of anemia
in patients with IBD and
low levels of serum
ferritin previously treated
for IBD-associated
anemia within 8 months
Hb < 13 g/dL < or
<12 g/dL ,
Target: time to
recurrence of anemia
Serum ferritin–triggered iron
therapy with ferric carboxy-
maltose is an effective and
safe treatment to prevent
recurrence of anemia
evaluated by Hb and serum
ferritin levels in patients with
IBD who have responded to
prior intravenous iron-
replacement therapy.
Iron supplementation did
not affect disease activity.
Reinisch64 Intravenous iron
isomaltoside (1000mg;
n¼ 219) or oral iron
sulfate (200mg daily;
n¼ 108)
327 patients with IBD
(103 CD, 224 UC in
quiescent to mild
disease activity)
8 weeks
Randomized, open-label,
comparative; endpoint
was compared by a
noninferiority assessment
with a margin of
–0.5 g/dL
Hb < 12 g/dL, TSAT
< 20%
Target: change of Hb
Noninferiority of intravenous
iron isomaltoside versus
oral iron was not
demonstrated as assessed
by Hb and TSAT.
Iron supplementation did
not affect disease activity.
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Authors
Route of
Administration
Number of Patients,
Disease Activity, and
Follow-Up Time (wk)
Design, Inclusion Criteria,
and End Point/Target Findings
Hetzel84 Intravenous ferumoxytol
(510mg; n¼ 406) or
intravenous iron sucrose
(200mg; n¼ 199)
605 patients, of whom 138
had GI disorders incl.
IBD (disease activity
not specified)
5 weeks
Randomized, open label,
nonblinded; endpoint:
achieving 2 g/dL
increase in Hb at week
5 compared with baseline
Hb < 10 g/dL, TSAT
< 20%
Target: proportion of
patents achieving
> 2 g/dL increase of Hb
Ferumoxytol is as capable
regarding safety and
efficacy (Hb) as iron
sucrose in IDA patients in
whom oral iron is
unsatisfactory or cannot
be used.
No differences of
side effects
between the two groups
Onken80 Intravenous ferric
carboxymaltose
(1500mg; n¼ 246) or
oral iron sulfate
(975mg daily; n¼ 253)
509 patients, of whom
53 had GI disorders incl.
IBD (disease activity
not specified)
5 weeks
Randomized, open-label,
active-controlled among
patients responding
inadequately to oral iron
for preceding 14 days
(Hb increase <1 g/dL)
Target: highest observed
Hb value from time of
intervention and day 35.
Hb < 11 g/dL, s-ferritin
< 100mg/L
Ferric carboxymaltose is safe
and superior to oral iron in
increasing Hb and s-ferritin
in IDA patients with
inadequate oral iron
response.
Worsening of disease not
reported.
Gasche51 Oral ferric maltol
(30mg b.i.d.; n¼ 64)
or placebo (n¼ 64).
128 IBD patients (70 CD,
58 UC) in remission or
mild to moderate disease
activity
12 weeks
Randomized, double-blind,
placebo-controlled
multicenter study among
patients with iron
deficiency anemia and
documented failure of
previous ferrous products
Hb 9.5–<12 g/dL for ,
or – <13 g/dL for < and
s-ferritin <30mg/L at
screening
Target: change of
Hb from screening to
week 12
Ferric maltol provided
clinically meaningful
improvements in Hb and
showed a favorable safety
profile (the latter
comparable to placebo).
Iron supplementation
did not
affect disease activity.
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Further, chronic fatigue caused by anemia may debilitate and
even worry patients with IBD as much as abdominal pain or
diarrhea.95 Therefore, the beneficial effect on quality of life
derived from the correction of anemia in patients with IBD may
be as important to patients as the control of their abdominal
symptoms.95
To tailor the most appropriate therapy for iron deficiency
and anemia in patients with IBD, some basic diagnostic
analyses are mandatory21,27,56 (Table 3). Thus, during active
inflammatory stages of IBD, laboratory measures of iron status
are more difficult to interpret because inflammation affects the
laboratory parameters of iron metabolism.96 In the presence of
chronic inflammation, the elevated transferrin levels character-
izing iron deficiency may not be found because patients with
low albumin levels tend to have lower transferrin concen-
trations.97 Moreover, the serum ferritin level, the most acces-
sible and well-known surrogate marker of stored iron,98 can be
normal or even increased in response to inflammation because
ferritin expression is stimulated by several cytokines even in the
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.presence of true iron deficiency.96 Therefore, although ferritin
is generally considered to be the best indicator of iron
deficiency, this parameter may not be reliable for the stored
compartment in the setting of active inflammatory conditions,
including IBD.11,96 Of note, both patients with inflammatory
anemia and true iron-deficiency anemia have low transferrin
saturation, which is a good indicator for a reduced availability of
iron for erythropoiesis and thus has been used in a number of
studies as a surrogate to determine the time to initiate iron
therapy.53,56,95,99,100
Comparative studies of intravenous versus oral iron
supplementation in the systematic review did not demonstrate
any significant difference in hemoglobin normalization favor-
ing the use of intravenous iron therapy57,64,69,72,79,92 unless
considered for patients with intolerance or an inadequate
response to oral supplementation or during active disease
stages. Moreover, a recent systematic review of randomized,
controlled trials with the aim of assessing safety has demon-
strated that intravenous iron therapy may increase the risk of
infection.101
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TABLE 3. SurrogateMarkers of Importance for Assessing Anemia Due to Either Possible Coexisting Iron Deficiency (IDA), Chronic
Disease (ACD), or Both (IDAþACD)
Values Compared With Normal Range
Laboratory Test IDA ACD IDAþACD Comments
Iron Low Low Low
Transferrin High Low to normal Low
Ferritin Low Normal to high Normal to high <30 ng/mL quiescent disease;
>30 ng/mL active disease
TSAT Low Low Low <16–20%; observe
circadian variation
sTfR/log ferritin >2 <1 >2
MCV/MHC Low Low to normal Low to normal
Reticulocyte Hb content (CHr) Low Normal Low
Vitamins (folate, B12, D) Normal Low to normal Low to normal
Acute-phase proteins Normal Normal to high Normal to high
Hepcidin Low

High Low to high

Might be undetectable in true
iron deficiency even in the
presence of inflammation
CHr¼ reticulocyte hemoglobin content; MCV¼ erythrocyte mean cell volume; MHC¼mean cell hemoglobin concentration; sTfR¼ soluble
Nielsen et al Medicine  Volume 94, Number 23, June 2015Because a great number of physicians are uncertain as to
which diagnostic procedures and treatment regimen they should
prescribe for their patients with iron-deficiency anemia,102 we
performed an updated extensive review of the literature pub-
lished in the last decade (during which novel approaches to
intravenous iron supplementation have been introduced). In an
independent screening and data extraction of references by 2
authors, only original prospective studies evaluating the treat-
ment of iron-deficiency anemia in patients with IBD with a
minimum observation time of 4 weeks were included, and the
outcome assessment comprised correction of iron deficits caus-
ing anemia in patients with IBD. In terms of limitations, the
studies included generally were characterized by small numbers
of enrolled patients, were published solely in the English
language, and were heterogeneous in design (ie, inclusion
criteria and iron compositions administered, such as oral and
low- or high-dose intravenous drugs), different enrollment
populations as well as different lengths of therapy, and out-
comes. Further, in some of the studies, a minimum 4-week
treatment period was employed, although it is questionable
whether such a short interval is always effective for the correc-
tion of iron deficiency in IBD, and thus the efficacy of the oral
supplementation may be underestimated compared with a full
treatment period of, for example, 3 months.
Based on our systematic review of the evidence, we
developed an algorithm to help physicians in identifying IBD
patients in need of iron supplementation and in selecting the
most appropriate therapy regimen (Figure 4). If intravenous iron
supplementation is considered, the use of older low-dose regi-
mens is not recommended from the point of view of clinical
practicality because a number of infusions might be needed over
several days or weeks. Thus, high-dose regimens result in fewer
infusions and increase the convenience and cost-effectiveness
of intravenous iron repletion.
transferrin receptor; TSAT¼ transferrin saturation.The optimal dosing strategy for intravenous compounds
depends on the type of preparation and patient body weight and
Hb concentration. The amount of iron needed to correct the Hb
10 | www.md-journal.comconcentration can be calculated using the Ganzoni equation,103
although this formula might underestimate the iron needed
when using a target Hb of 13 g/dL and iron stores of
500mg.64 Other, more simple schemes for the estimation of
total iron need have been published.56,104 It should be men-
tioned that among patients with iron-deficiency anemia who are
unresponsive even to intravenous iron supplementation (Hb
increase  2 g/dL within 4 weeks), treatment with erythropoie-
tin after ruling out other causes of anemia such as vitamin
deficiencies, may be an option (Figure 4).105–107
Finally, it should be highlighted that iron deficiency in IBD
often relapses after iron replenishment.78 Consequently, period-
ically monitoring, for example, every 3 months for a year and
again after a year once the Hb value is normalized and iron
stores are replenished to assess if retreatment is required.98
However, we lack solid data on when to stop iron supplement-
ation therapy in order to avoid iron overloading, which may
cause side effects because of the potential of the metal to
catalyze the formation of toxic radicals.108 Recent guidelines
on the management of anemia in dialysis patients suggest that
ferritin levels of up to 500 ng/mL appear to be safe. This limit
also appears to be a useful upper a threshold in the management
of patients with IBD and anemia.109 Of note, in a recently
published prospective single-center study, iron supplementation
in chronic kidney disease patients was associated with a sig-
nificant reduction in overall mortality.110 However, prospective
studies will be necessary to clarify the impact of anemia
correction and iron supplementation on the course of IBD
and patient outcomes,102 as well as the definition of clinical
endpoint, in order to optimize anemia management and iron
supplementation in IBD patients.
CONCLUSIONS
The control of inflammation is a key objective in the
treatment of IBD. Because iron-deficiency anemia has a con-
siderable impact on patient quality of life, a thorough and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 4. Algorithm for the treatment of anemia with iron deficiency in IBD. The decision tree provides a ready-to-use tool for clinicians
to find the most appropriate therapy for patients with anemia/iron deficiency and IBD based on the data contained in this systematic
2g
Medicine  Volume 94, Number 23, June 2015 Treatment of Iron-Deficiency Anemia in IBDcomplete diagnostic and therapeutic strategy should be fol-
lowed to help patients attain as normal a life as possible.
Given the novel intravenous iron-replacement regimens
introduced within the last 10 years, physicians may be uncertain
concerning the optimal iron-replacement regimen should be
prescribed. Based on the data presented herein, oral iron therapy
should be preferred for patients with mild iron deficiency
anemia (Hb  10 g/dL) in quiescent disease stages unless they
are intolerant or have an inadequate response (Hb increase <
2 g/dL within 4 weeks),111 whereas intravenous iron supple-
mentation may be of advantage in patients with aggravated iron
deficiency anemia or flaring IBD (Hb < 10 g/dL) because
inflammation hampers intestinal iron absorption.10,112,113 In
our systematic review, only 1 study showed oral iron supple-
mentation to worsen disease activity in 2 patients with UC,54
although quality of life improved significantly in the same
group of patients, and intravenous iron supplementation seems
to be safe in patients with active IBD. Finally, based on the
review. Insufficient response is defined as a hemoglobin increase <
specified in the text. IBD¼ inflammatory bowel disease.available data, iron therapy can be administered concomitantly
with TNF inhibitors,93 a class of drugs used increasingly in the
management of IBD.114
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.In summary, gastroenterologists treating patients with IBD
need to pay attention to the management of anemia and iron
deficiency for improvement in the general well-being of their
patients a matter which frequently does not gain the attention it
deserves. Here, we have presented an evidence-based algorithm
for treatment of iron deficiency anemia in patients with IBD, but
because of the high risk of anemia recurrence in this cohort,
further clinical trials are warranted in an effort to optimize the
treatment schedule in these patients.
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